Adipogen/Genipin/AG-CN2-0481-M100/100 mg
商品编号：
AG-CN2-0481-M100
品牌：
Adipogen Inc
市场价：
¥3000.00
美元价：
1800.00
产品分类：
其他试剂
公司分类：
Other_reagents
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
| Product Details | |
|---|---|
| Synonyms | (+)-Genipin; Methyl (1S,2R,6S)-2-hydroxy-9-(hydroxymethyl)-3-oxabicyclo[4.3.0]nona-4,8-diene-5-carboxylate |
| Product Type | Chemical |
| Properties | |
| Formula | C11H14O5 |
| MW | 226.2 |
| CAS | 6902-77-8 |
| RTECS | GY5828000 |
| Source/Host Chemicals | Isolated from Gardenia jasminoides Ellis fruits. |
| Purity Chemicals | ≥98% (HPLC) |
| Appearance | White to off-white solid. |
| Solubility | Soluble in DMSO (50mg/ml), ethanol (5mg/ml), methanol or acetone. Slightly soluble in water. |
| InChi Key | AZKVWQKMDGGDSV-BCMRRPTOSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice |
Keep cool and dry. Protect from light. |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
- Cell permeable inhibitor of uncoupling protein 2 (UCP2).
- Increases glucose-stimulated insulin secretion, mitochondrial membrane potential and ATP levels in pancreatic island cells.
- Anticancer, antimetastatic and anti-angiogenic agent. Increases Bax/Bcl-2 ratio and induces PARP cleavage and caspase-3- and caspase-9-mediated apoptosis in non-small cell lung cancer (NSCLC) cells. Sensitizes multidrug-resistant cancer cells to cytotoxic agents through UCP2 inhibition. Suppresses the tumor promoting function of UCP2 in a cellular model of Warburg effect.
- Anti-inflammatory agent. Upregulates nNOS (neuronal nitric oxide synthase/NOS I) and decreases acute inflammation through inhibition of LPS-induced NF-κB activity. Inhibits toll-like receptor (TLR) signaling and the production of pro-inflammatory cytokines, preventing sepsis and increasing survival in animal models of infection.
- Modulates NLRP3 inflammasome activation and ATP- or H2O2-mediated IL-1β release. Inhibits NLRP3 and NLRC4 inflammasome activation via autophagy suppression.
- Antiviral compound. Chemical promoter of Epstein-Barr virus (EBV) lytic cycle activation and suppressor of EBV infection.
- Shown to have wound healing, neuroprotective, antidepressant, anti-osteoporotic and antioxidative activities.
- Protein, collagen, gelatin and chitosan natural cross-linking agent. 5,000-10,000 times less cytotoxic than any other crosslinking agents, with favorable properties of use in the range of pH 7.4-8.5 and temperatures between 25-45°C.
- Shown to be useful in the construction of novel drug delivery systems, as the raw material for gardenia blue pigment preparation and as the intermediate for alkaloid syntheses.
- Produces blue colored pigments by binding to amino acids. Simple, safe, sensitive and stable alternative for colorimetric determination of amino acids.
- Shown in forensic research to be a novel fingerprint reagent with colorimetric and fluorogenic activity.
Product References
- Naturally occurring oxygen heterocyclics. IX. Isolation and characterization of genipin: C. Djerassi, et al.; J. Org. Chem. 25, 2174 (1960)
- Prevention of the neurotoxicity of the amyloid beta protein by genipin: M. Yamazaki, et al.; Biol. Pharm. Bull. 24, 1454 (2001)
- Colorimetric determination of amino acids using genipin from Gardenia jasminoides: S.W. Lee, et al.; Anal. Chim. Acta 480, 267 (2003)
- Genipin-a novel fingerprint reagent with colorimetric and fluorogenic activity: J. Almog, et al.; J. Forensic Sci. 49, 255 (2004)
- Cyclic GMP-dependent neurite outgrowth by genipin and nerve growth factor in PC12h cells: M. Yamazaki, et al.; Eur. J. Pharmacol. 488, 35 (2004)
- Antiinflammatory effects of genipin, an active principle of gardenia: H.J. Koo, et al.; Eur. J. Pharmacol. 495, 201 (2004)
- Genipin inhibits UCP2-mediated proton leak and acutely reverses obesity- and high glucose-induced beta cell dysfunction in isolated pancreatic islets: C.Y. Zhang, et al.; Cell Metab. 3, 417 (2006)
- Genipin exhibits neurotrophic effects through a common signaling pathway in nitric oxide synthase-expressing cells: M. Yamazaki & K. Chiba; Eur. J. Pharmacol. 581, 255 (2008)
- Neuroprotective action of genipin on tunicamycin-induced cytotoxicity in neuro2a cells: M. Tanaka, et al.; Biol. Pharm. Bull. 32, 1220 (2009)
- Antidepressant-like effect of genipin in mice: J.S. Tian, et al.; Neurosci. Lett. 479, 236 (2010)
- Genipin induced apoptosis associated with activation of the c-Jun NH2-terminal kinase and p53 protein in HeLa cells: H. Cao, et al.; Biol. Pharm. Bull. 33, 1343 (2010)
- Genipin-induced inhibition of uncoupling protein-2 sensitizes drug-resistant cancer cells to cytotoxic agents: R.J. Mailloux, et al.; PLoS One 5, e13289 (2010)
- Cellular model of Warburg effect identifies tumor promoting function of UCP2 in breast cancer and its suppression by genipin: V. Ayyasamy, et al.; PLoS One 6, e24792 (2011)
- Genipin attenuates sepsis by inhibiting Toll-like receptor signalling: T.H. Kim, et al.; Mol. Med. 18, 455 (2012)
- Up-regulation of TIMP-1 by genipin inhibits MMP-2 activities and suppresses the metastatic potential of human hepatocellular carcinoma: N. Wang, et al.; PLoS One 7, e46318 (2012)
- Genipin - the natural water soluble cross-linking agent and its importance in the modified drug delivery systems: an overview: B. Manickam, et al.; Curr. Drug Deliv. 11, 139 (2014) (Review)
- Genipin inhibits RANKL-induced osteoclast differentiation through proteasome-mediated degradation of c-Fos protein and suppression of NF-κB activation: C.H. Lee, et al.; J. Pharmacol. Sci. 124, 344 (2014)
- Genipin as a novel chemical activator of EBV lytic cycle: M. Son, et al.; J. Microbiol. 53, 155 (2015)
- Genipin suppresses NLRP3 inflammasome activation through uncoupling protein-2: V. Rajanbabu, et al.; Cell Immunol. 297, 40 (2015)
- Genipin inhibits NLRP3 and NLRC4 inflammasome activation via autophagy suppression: S.X. Yu, et al.; Sci. Rep. 5, 17935 (2015)
品牌介绍
Adipogen公司由三个子公司组成，分别是Adipogen,Inc.(韩国),AdipogenSA(瑞士)和 AdipogenCorporation(美国圣地亚哥)。总部设在美国，运营总部在瑞士利斯塔尔。Adipogen公司专门从事生命科学研究试剂的开发，如癌症、免疫、炎症、代谢疾病（糖尿病、肥胖）、干细胞和神经退行性疾病等领域。其重点关注开发创新优质的ELISA试剂盒。另外，也可提供抗体和蛋白产品，Adipogen拥有自己的化学实验室，致力于开发创新型小分子化合物。
联络我们
